

Paris, march 9th, 2015

Disclosure of the total number of voting rights and the number of shares of the share capital

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has published information on the total number of voting rights and number of shares comprising the share capital on march 9th 2015, in accordance with the provisions of article 223-16.

Date	Number of shares	Number of voting rights	
		Theoretical	
March 9 th 2015	6,859,962		7,507,784
		Exercisable ⁽¹⁾	7,501,710

(1) The total number of voting rights is calculated based on the total shares minus shares without voting rights treasury shares. On March 9th 2015, 6,074 shares, representing a total of 6,074 voting rights, were registered under the liquidity contract assigned to the brokerage Aurel BGC.

CONTACTS

Quantum Genomics

Lionel Ségard
Chairman & Chief Executive Officer
01 60 13 76 80

Quantum Genomics

Marc Karako
CFO – Investor Relations
01 60 13 76 84
marc.karako@quantum-genomics.com

ACTUS finance et communication

Jean-Michel Marmillon
Press Relations
01 53 67 36 73
jmmarmillon@actus.fr

ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).